EMA Starts Review of Dexamethasone as COVID-19 Treatment
EMA has started a review of dexamethasone as a treatment for adults with COVID-19 who require respiratory support and have been admitted to hospital.
The European Medicines Agency (EMA) has announced in a July 24, 2020 press release that it has started a review of dexamethasone as a treatment for adults with COVID-19 who require respiratory support and have been admitted to hospital.
Specifically, the regulatory agency is reviewing data from the RECOVERY study arm that looked at the effects of adding dexamethasone to usual care in adults receiving invasive ventilation, in those receiving oxygen (e.g., through a mask), or in those receiving no oxygen. In the study, any deaths that happened 28 days after starting dexamethasone treatment were recorded and preliminary results indicate that dexamethasone reduced mortality in patients receiving respiratory support compared with usual care.
With this review, EMA hopes to provide an opinion on the RECOVERY study and also on the potential use of dexamethasone for the treatment of adults with COVID-19. More information will be presented by the agency when available.
Source: EMA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
